Lack of association between the rs1842681 polymorphism of the LOC105372028 gene and functional outcomes after stroke

The rs1842681 polymorphism of the LOC105372028 gene was found to correlate with a 3-month functional stroke outcome in a genome-wide association study meta-analysis performed by the GISCOME study. Although the STRONG study confirmed these results, a study in a Chinese population reported no such correlation. We prospectively examined the correlation between the rs1842681 polymorphism of the LOC105372028 gene and the 3-month ischemic stroke functional outcome in a Polish population. In 1037 IBioStroke participants, we examined two multivariate logistic regression models, predicting excellent (mRS: 0–1 vs. 2–6) and good (mRS: 0–2 vs. 3–6) outcomes. In an univariate analysis the rs1842681 polymorphism, among several other parameters available in acute stroke, was associated with an excellent outcome in an additive model (AG vs. GG genotype distribution) (OR = 0.74; 95%CI: 0.57–0.97, p = 0.027), in a dominant model (AG + AA vs. GG) (OR = 0.75; 95%CI: 0.58–0.96, p = 0,025) and in A/G allele frequencies (OR = 0.81, 95%CI:0.66–0.99, p = 0.044), however, it was not associated with good outcome in an additive, dominant and recessive models, as well as the A/G allele frequencies. The multivariate analyses, including additive mode (AM) and dominant mode (DM) of inheritance showed, that excellent outcome was associated with younger age (AM: OR = 0.95; 95%CI:0.94–0.97, p < 0.001; DM: OR = 0.95; 95%CI:0.94–0.97, p < 0.001), longer education (AM: OR = 1.07; 95%CI:1.01–1.14, p = 0.019; AD: OR = 1.07; 95%CI:1.01–1.14, p = 0.019), neurological improvement within 24 h (AM: OR = 1.11; 95%CI: 1.08–1.15, p < 0.001; AD: OR = 1.11; 95%CI: 1.07–1.15, p < 0.001), absence of hemorrhagic transformation (AM: OR = 0.48; 95%CI: 0.30–0.77, p = 0.003; AD: OR = 0.49; 95%CI: 0.31–0.79, p = 0.003), absence of infection (AM: OR = 0.21; 95%CI: 0.14–0.31, p < 0.001; AD: OR = 0.21; 95%CI: 0.14–0.31, p < 0.001), lower WBC count (AM: OR = 0.90; 95%CI:0.85–0.96, p < 0.001; AD: OR = 0.90; 95%CI:0.85–0.96, p < 0.001), and lower glucose levels (AM: OR = 1.00; 95%CI: 0.99-1.00, p = 0.035; DM: OR = 1.00; 95%CI: 0.99-1.00, p = 0.037); while good outcome – with younger age (OR = 0.96; 95%CI: 0.94–0.97, p < 0.001); longer education (OR = 1.10; 95%CI:1.03–1.17, p = 0.004); neurological improvement within 24 h (OR = 1.13; 95%CI: 1.09–1.17, p < 0.001), absence of infection (OR = 0.20; 95%CI: 0.14–0.30, p < 0.001) and lower WBC count (OR = 0.87; 95%CI: 0.82–0.93, p < 0.001). The influence of the rs1842681 variant on the 3-month functional stroke outcome was not confirmed in the Polish population.